526 related articles for article (PubMed ID: 23775406)
21. Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.
Cortot AB; Younes M; Martel-Planche G; Guibert B; Isaac S; Souquet PJ; Commo F; Girard P; Fouret P; Brambilla E; Hainaut P; Soria JC
Clin Lung Cancer; 2014 Mar; 15(2):124-30. PubMed ID: 24169260
[TBL] [Abstract][Full Text] [Related]
22. Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma.
Sun JM; Lira M; Pandya K; Choi YL; Ahn JS; Mao M; Han J; Park K; Ahn MJ; Kim J
Lung Cancer; 2014 Feb; 83(2):259-64. PubMed ID: 24300132
[TBL] [Abstract][Full Text] [Related]
23. Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas.
Sonobe M; Kobayashi M; Ishikawa M; Kikuchi R; Nakayama E; Takahashi T; Menju T; Takenaka K; Miyahara R; Huang CL; Okubo K; Bando T; Date H
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S347-54. PubMed ID: 21607772
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of ANCCA/ATAD2 in endometrial carcinoma and its correlation with tumor progression and poor prognosis.
Shang P; Meng F; Liu Y; Chen X
Tumour Biol; 2015 Jun; 36(6):4479-85. PubMed ID: 25934333
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
Schneider CP; Heigener D; Schott-von-Römer K; Gütz S; Laack E; Digel W; Guschall WR; Franke A; Bodenstein H; Schmidtgen C; Reck M
J Thorac Oncol; 2008 Dec; 3(12):1446-53. PubMed ID: 19057271
[TBL] [Abstract][Full Text] [Related]
26. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.
Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
Eur J Cancer; 2014 May; 50(7):1361-9. PubMed ID: 24548766
[TBL] [Abstract][Full Text] [Related]
27. Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma.
Kim MH; Shim HS; Kang DR; Jung JY; Lee CY; Kim DJ; Lee JG; Bae MK; Kim HR; Lim SM; Kim EY; Park JS; Chung KY; Kim HJ; Kim JH; Cho BC
Lung Cancer; 2014 Mar; 83(3):389-95. PubMed ID: 24462463
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas.
Woo T; Okudela K; Yazawa T; Wada N; Ogawa N; Ishiwa N; Tajiri M; Rino Y; Kitamura H; Masuda M
Lung Cancer; 2009 Sep; 65(3):355-62. PubMed ID: 19162366
[TBL] [Abstract][Full Text] [Related]
29. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas.
Wang R; Pan Y; Li C; Zhang H; Garfield D; Li Y; Ye T; Hu H; Luo X; Li H; Zhang Y; Zhang J; Zhou X; Shen L; Pao W; Sun Y; Chen H
J Thorac Oncol; 2014 Jun; 9(6):760-8. PubMed ID: 24481316
[TBL] [Abstract][Full Text] [Related]
30. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
31. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
[TBL] [Abstract][Full Text] [Related]
32. High expression of CHRNA1 is associated with reduced survival in early stage lung adenocarcinoma after complete resection.
Chang PM; Yeh YC; Chen TC; Wu YC; Lu PJ; Cheng HC; Lu HJ; Chen MH; Chou TY; Huang CY
Ann Surg Oncol; 2013 Oct; 20(11):3648-54. PubMed ID: 23775407
[TBL] [Abstract][Full Text] [Related]
33. The new histologic classification of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifies tumors with different mutation status: the experience of a French cohort.
Mansuet-Lupo A; Bobbio A; Blons H; Becht E; Ouakrim H; Didelot A; Charpentier MC; Bain S; Marmey B; Bonjour P; Biton J; Cremer I; Dieu-Nosjean MC; Sautès-Fridman C; Régnard JF; Laurent-Puig P; Alifano M; Damotte D
Chest; 2014 Sep; 146(3):633-643. PubMed ID: 24676429
[TBL] [Abstract][Full Text] [Related]
34. HNF4α as a marker for invasive mucinous adenocarcinoma of the lung.
Sugano M; Nagasaka T; Sasaki E; Murakami Y; Hosoda W; Hida T; Mitsudomi T; Yatabe Y
Am J Surg Pathol; 2013 Feb; 37(2):211-8. PubMed ID: 23108025
[TBL] [Abstract][Full Text] [Related]
35. Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.
Yu HA; Sima CS; Hellmann MD; Naidoo J; Busby N; Rodriguez K; Riely GJ; Kris MG
Cancer; 2015 Jun; 121(12):2078-82. PubMed ID: 25781862
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
[TBL] [Abstract][Full Text] [Related]
37. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
Lee SY; Kim MJ; Jin G; Yoo SS; Park JY; Choi JE; Jeon HS; Cho S; Lee EB; Cha SI; Park TI; Kim CH; Jung TH; Park JY
J Thorac Oncol; 2010 Nov; 5(11):1734-40. PubMed ID: 20881644
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status.
Onitsuka T; Uramoto H; Ono K; Takenoyama M; Hanagiri T; Oyama T; Izumi H; Kohno K; Yasumoto K
J Thorac Oncol; 2010 May; 5(5):591-6. PubMed ID: 20150826
[TBL] [Abstract][Full Text] [Related]
39. Erythropoietin-Producing Hepatocellular A1 is an Independent Prognostic Factor for Gastric Cancer.
Nakagawa M; Inokuchi M; Takagi Y; Kato K; Sugita H; Otsuki S; Kojima K; Uetake H; Sugihara K
Ann Surg Oncol; 2015 Jul; 22(7):2329-35. PubMed ID: 25391265
[TBL] [Abstract][Full Text] [Related]
40. The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features.
Ma Z; Zhang Y; Deng C; Fu F; Deng L; Li Y; Chen H
J Thorac Cardiovasc Surg; 2022 Jan; 163(1):e73-e85. PubMed ID: 32739163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
